Tillotts Pharma (Switzerland)

Recent papers from Tillotts Pharma (Switzerland)

1. The ongoing challenge of Clostridioides difficile infection in Austria: economic evaluation of two recommended treatment pathwaysJournal of Medical Economics · 2026
2. Comparative Efficacy of Mesalazine and Ozanimod following Induction Treatment in Mesalazine-Exposed Advanced Therapy-Naïve Adult Ulcerative Colitis Patients.2025
3. Multiple episodes of paediatric Clostridioides difficile infection (pCDI) in the context of autoimmune polyendocrine syndrome type 1BMJ Case Reports · 2025
4. CD371-targeted CAR T cells secreting interleukin-18 exhibit robust expansion and clear refractory acute myeloid leukemiaBlood · 2025
5. The Impact of Mesalazine Pill Burden on Compliance in Inflammatory Bowel Disease PatientsInflammatory Intestinal Diseases · 2025
6. Investigating accumulation of budesonide and tacrolimus in an ex vivo porcine oesophageal model: Translational potential for local application of drugs to treat eosinophilic oesophagitisEuropean Journal of Pharmaceutical Sciences · 2025
7. Similar Efficacy of Mesalazine in Adult and Older Adult Ulcerative Colitis Patients: Post Hoc Analysis of a Randomized Noninferiority Trial of 1600 mg vs 400 mg TabletsInflammatory Bowel Diseases · 2024
8. A cost-utility analysis of two Clostridioides difficile infection guideline treatment pathwaysClinical Microbiology and Infection · 2023
9. Lack of Benefit for Early Escalation to Advanced Therapies in Ulcerative Colitis: Critical Appraisal of Current EvidenceJournal of Crohn s and Colitis · 2023
10. Assessing the Clinical and Endoscopic Efficacy of Extended Treatment Duration with Different Doses of Mesalazine for Mild-to-Moderate Ulcerative Colitis beyond 8 Weeks of InductionInflammatory Intestinal Diseases · 2023
11. Medication Formulation Preference of Mild and Moderate Ulcerative Colitis Patients: a European SurveyInflammatory Intestinal Diseases · 2023
12. Topical Wound Treatment with a Nitric Oxide-Releasing PDE5 Inhibitor Formulation Enhances Blood Perfusion and Promotes Healing in MicePharmaceutics · 2022
13. Targeted colonic release formulations of mesalazine – A clinical pharmaco-scintigraphic proof-of-concept study in healthy subjects and patients with mildly active ulcerative colitisInternational Journal of Pharmaceutics · 2022
14. A Dual-Acting Nitric Oxide Donor and Phosphodiesterase 5 Inhibitor Activates Autophagy in Primary Skin FibroblastsInternational Journal of Molecular Sciences · 2022
15. Dual‐Mode Vasodilator M119 Delivery to Hair Follicle via Dissolving Microneedle for Advanced Alopecia TreatmentAdvanced Therapeutics · 2022
16. Colonic delivery of metronidazole-loaded capsules for local treatment of bacterial infections: A clinical pharmacoscintigraphy studyEuropean Journal of Pharmaceutics and Biopharmaceutics · 2021
17. Differential regulation of JAK/STAT-signaling in patients with ulcerative colitis and Crohn’s diseaseWorld Journal of Gastroenterology · 2020
18. Modern use of 5-aminosalicylic acid compounds for ulcerative colitisExpert Opinion on Biological Therapy · 2019
19. Patient Preference and Physician Perceptions of Patient Preference for Oral Pharmaceutical Formulations: Results from a Real-Life SurveyInflammatory Intestinal Diseases · 2018
20. Patient Reported Outcome Measures (PROMs) in Inflammatory Bowel Disease: New DataJournal of Crohn s and Colitis · 2016